SCHEMBL24714780

SCHEMBL24714780

Oc1nc(-c2cn3ncnc3c(Cc3cccc(F)c3)n2)ncc1F

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP1 P22413 1/20 0.34
BRD4 O60885 1/20 0.34
NTRK1 P04629 1/20 0.33
GRIA1 P42261 1/20 0.33
ADCY10 Q96PN6 1/20 0.32
ALDH1A1 P00352 3/20 0.32
KDM4E B2RXH2 1/20 0.32
HPGD P15428 1/20 0.32
MAPK1 P28482 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
HSD17B10 Q99714 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ALKBH1 Q13686 1/20 0.32
EGFR P00533 2/20 0.32
ERBB2 P04626 2/20 0.32
TGFBR1 P36897 1/20 0.31
MAPK14 Q16539 1/20 0.31
ABL1 P00519 1/20 0.31
SRC P12931 1/20 0.31
KDM4C Q9H3R0 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30854932 1.00 ENPP1 (0.34) ENPP1BRD4NTRK1GRIA1ADCY10
SCHEMBL24714366 0.90
SCHEMBL30854933 0.85 NTRK1 (0.34) NTRK1ALKBH1
SCHEMBL24714783 0.85 NTRK1 (0.34) NTRK1ALKBH1
SCHEMBL24714781 0.83 ALKBH1 (0.32) ALKBH1TGFBR1MAPK14
SCHEMBL30854937 0.83 ALKBH1 (0.32) ALKBH1TGFBR1MAPK14
SCHEMBL22732867 0.82 HPGD (0.33) BRD4NTRK1ADCY10ALDH1A1KDM4E
SCHEMBL24714970 0.82 GRIA1 (0.38) BRD4GRIA1ADCY10KDM4EKDM4C
SCHEMBL30854939 0.82 GRIA1 (0.38) BRD4GRIA1ADCY10KDM4EKDM4C
SCHEMBL24714365 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208979-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2024-06-27 US disclosed
US-20240207265-A1 TREATMENT OF CNS DISEASES WITH sGC STIMULATORS TISENTO THERAPEUTICS INC. 2024-06-27 US disclosed
US-20240207265-A1 TREATMENT OF CNS DISEASES WITH sGC STIMULATORS TISENTO THERAPEUTICS INC. 2024-06-27 US disclosed
US-20240208979-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2024-06-27 US disclosed
WO-2022225902-A1 TREATMENT OF CNS DISEASES WITH SGC STIMULATORS CYCLERION THERAPEUTICS, INC. (US) 2022-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208979-A1 sGC STIMULATORS GMPS, PRKG1, CGAS ENPP1 409/4885BRD4 3809/4885NTRK1 2826/4885
US-20240207265-A1 TREATMENT OF CNS DISEASES WITH sGC STIMULATORS GUCY1A2, GUCY1A1, GUCY1B2 ENPP1 795/4885BRD4 4499/4885NTRK1 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.